OTraces PR Campaign — Strategic Plan

How each release works as a campaign — not just a press drop

Each PR is a hub: outreach happens before it lands, the release sets the news during release week, and amplification + follow-up convert attention into real conversations after. PRs are anchored to industry events so each one lands 2–3 weeks before the right audience gathers.

Drafted Press Releases on File

Six drafts confirmed and ready for the campaign

📄 6 documents on file

PR 1ADA — OTraces
ADA Poster OTraces — Tallon Poster Presentation
1 ADA Poster OTraces - PR OTraces Tallon Poster Presentation.docx
PR 1ADA — Tallon
ADA Poster Tallon — Erin Tallon ADA Poster Presentation
1 ADA Poster Tallon - PR Erin Tallon ADA poster presentation.docx
PR 2FL Grant — General
FL Grant — Press Release FDOH General Audience
2 FL Grant General - Press Release FDOH general audience.docx
PR 2FL Grant — Investor
FL Grant — Press Release FDOH Grant Investor
2 FL Grant Investor - Press Release FDOH Grant investor (1).docx
PR 3Labcorp
Labcorp — Press Release FDOH Labcorp Selection
3 Labcorp - Press Release FDOH Labcorp selection.docx
PR 4OTraces Capabilities
OTraces Capabilities — Investor Focused
4 OTraces Capabilities - Press Release capabilities investor focused.docx

Next Release

Aug 4

OTraces Technology — Platform Capabili

Days Until ADA

Email partners THIS WEEK

Days Until BIO

Book BIO meetings now

PR Cadence

3 wks

Event-anchored, room to breathe

Event-locked.This release date cannot move. American Diabetes Association (ADA) Scientific Sessions open Thu Jun 5 — the poster news goes cold the moment the conference opens. Releasing Mon Jun 1 gives journalists arriving for the show 3 days to see it in their inbox before the noise starts.

Monday June 1, 2026 — 4 days before ADA opens

ADA 2026 Poster — Two parallel releases for two audiences

3a: Tallon-centered → scientific media (EurekAlert)3b: OTraces-centered → business/investor media (GlobeNewswire)

PartnersInvestors

Before — Build the runway

→This week: email Sanofi, Vertex, Provention, MacroGenics — request meetings at ADA
→Coordinate with Erin Tallon for joint partner meetings
→Children's Mercy + U Florida press offices for co-distribution
→Fill in About OTraces boilerplate on 3b; add spokesperson quote
→Build day-of media pitch list: Diabetes Care editor, Endocrine Today, JDRF research news, diaTribe, Fierce Biotech T1D beat. Draft personalized pitch angles for each.

During — Release week

PRESS RELEASE

Mon Jun 1 — ADA Poster PR goes live (3a via EurekAlert through Children's Mercy press office; 3b via GlobeNewswire + LinkedIn the same day)

→📞 Day-of media pitch push: Sasha + Alan personally email each pre-built target list reporter within 2 hours of the wire hitting. Subject line references their recent coverage; body offers Alan as expert source for follow-up. (Proven tactic: BioBuzz-style day-of pitching consistently 3–5× the pickup of wire-only distribution.)

EVENT — CONVERT ATTENTION

Jun 5–8 — American Diabetes Association (ADA) Scientific Sessions, New Orleans — Alan attends with pre-booked partner meetings. PR drops 4 days before the conference opens.

Target audience here: Sanofi T1D, Vertex, Provention/Sanofi, MacroGenics, Lilly Diabetes, Novo Nordisk, JDRF research office.

→Erin Tallon posts on her LinkedIn; Alan reshares

After — Convert attention

→Follow up with everyone who stopped by the poster within 48 hours
→Pitch Diabetes Care editor for news coverage
→Plant seed for PR #6 (TrialNet collaboration release in November)
→Capture quotes/photos for LinkedIn content

Named Type 1 Diabetes (T1D) pharma targets (meet at ADA)

Sanofi T1DVertexProvention/SanofiMacroGenicsLilly DiabetesNovo Nordisk

Distribution channels

EurekAlertDiabetes CareJDRFdiaTribeEndocrine Today

Owner: Sasha (drafts) + Alan + Erin (approve)

Tuesday June 16, 2026 — 6 days before BIO opens

Florida Grant — Dual Release: Investor + General Audience

One press release. Two targeted distributions to non-overlapping audiences. Two existing drafts (investor framing + general-audience framing) cover the same news with different lead paragraphs and quote attribution. Each draft goes via the GlobeNewswire distribution list built for its audience. Investor readers won't see the general-audience cut; general health press won't see the investor cut. One news moment, two precisely-targeted hits.

Investor cut: GlobeNewswire investor outlets + Alan personal LinkedIn — "$2M non-dilutive validates $5B prostate biopsy market"General cut: GlobeNewswire regional/health verticals + Florida press — "Reducing unnecessary prostate biopsies for Florida men"

InvestorsPartnersGrants

Before — Build the runway

→Alan to send GlobeNewswire account info (company name, address, phone, website, logo, billing contact — list sent to Alan Apr 9)
→Secure Ken Pienta second quote for investor cut per Alan's stated intent
→Confirm PI name for general-audience cut (Dr. Anthony Schwartz?)
→Coordinate with Florida Department of Health (FDOH) comms on timing
→Draft Alan's LinkedIn pulse article: "What $2M of non-dilutive capital actually changes"
→Build day-of media pitch list — TWO lists, one per cut. Investor cut: Endpoints News, STAT, BioSpace, Fierce Biotech, The Long Run, BioWorld. General cut: Florida Trend, Tampa Bay Business Journal, MedCity News, Florida Health News, Modern Healthcare, Healthcare Dive. Draft personalized pitch angle for each reporter (reference their recent coverage, offer Alan as source).
→Draft payer-economics one-pager for health-system follow-up

During — Release week

PRESS RELEASE

Tue Jun 16 AM — Investor cut goes live on GlobeNewswire (investor + financial distribution) + Alan personal LinkedIn

PRESS RELEASE

Tue Jun 16 AM — General cut goes live on GlobeNewswire (regional + health verticals) + Florida press + OTraces page LinkedIn

→📞 Day-of media pitch push (within 2 hours of each wire): Sasha + Alan personally email every reporter on both pre-built lists. Different angle per cut. (BioBuzz-proven tactic — typically 3–5× the pickup of wire-only.)

→OTraces page cross-posts both with audience-targeted captions

→Email to warm investor list with personal note from Alan

→Direct outreach to Florida health systems

After — Convert attention

→Track inbound DMs across both audiences (Terry monitors)

EVENT — CONVERT ATTENTION

Jun 22–25 — BIO International Convention (San Diego) — Alan attends with the FL Grant news as conversation opener for BOTH audiences. Book One-on-One Partnering meetings NOW.

Target audience here: Investors (Casdin, Section 32, ARCH, RA Capital, Perceptive, Sands) + diagnostic partners (Quest, Roche Dx, Abbott Dx) + Florida health systems (AdventHealth, Moffitt).

→Alan publishes follow-up LinkedIn article mid-week

→Pitch The Long Run podcast (investor angle) + MedCity News (health angle)

→Position OTraces for next FDOH grant cycle

Named investor targets

Casdin CapitalSection 32ARCH VentureRA CapitalPerceptiveSands Capital

Named partner + payer + health system targets

Quest DiagnosticsRoche DxAbbott DxFlorida BlueHumanaAdventHealthMoffitt

Owner: Alan (voice) + Sasha (drafts/distribution)

Tuesday July 14, 2026 (pre-ADLM, 12 days before lab industry's biggest show)

Labcorp Partner Selection

Joint distribution with Labcorp if approvedHeadline: Tier-1 lab chose OTraces — proof of execution

PartnersInvestors

Before — Build the runway

→Get Labcorp comms team signoff on language
→Ask if Labcorp will co-distribute or quote
→Brief Labcorp on what's already in the campaign so they understand context
→Build day-of media pitch list: 360Dx, GenomeWeb, CAP Today, Dark Daily, The Dark Report, Diagnostics World, BioWorld MedTech. Draft personalized pitch angles emphasizing the Tier-1 lab validation story.

During — Release week

PRESS RELEASE

Tue Jul 14 — Labcorp Selection PR goes live on GlobeNewswire + (ideally) Labcorp co-release

→📞 Day-of media pitch push (within 2 hours of wire): Sasha + Alan personally email every reporter on pre-built lab/IVD trade list. Personalized subject + body for each. (BioBuzz-proven tactic — typically 3–5× the pickup of wire-only.)

→Ask Labcorp to repost on their LinkedIn — 10x's the reach

After — Convert attention

→Approach Quest + Sonic + BioReference using Labcorp as proof point

EVENT — CONVERT ATTENTION

Oct 3–6 — College of American Pathologists (CAP) Annual Meeting, Wynn Las Vegas — Alan attends; Platform PR sets up the strategic conversation for lab medical directors.

Target audience here: Reference lab medical directors at Quest, Labcorp, Sonic Healthcare, Mayo Labs.

→Sets up PR #5 (partnership ask) with execution credibility

Next-wave lab targets

Quest DiagnosticsSonic HealthcareBioReferenceMayo LabsCleveland Clinic Labs

Distribution channels

CAP TodayDark Daily360DxGenomeWeb

Owner: Alan (Labcorp signoff) + Sasha

Tuesday August 4, 2026 (follow-up to Labcorp news; sets up CAP outreach)

OTraces Technology — Platform Capabilities Story

GlobeNewswire + Alan LinkedIn pulse articleRepositions OTraces from "one test" to "platform"

InvestorsPartners

Before — Build the runway

→STRIP "Moscow" from Gertsen Institute references
→Replace Keith Lingenfelter as contact with Alan (Keith passed Nov 2025)
→Refresh contact block + add updated About OTraces
→Draft Alan's long-form LinkedIn article companion piece
→Build day-of media pitch list: 360Dx, GenomeWeb, BioWorld MedTech, In Vivo, Endpoints News, BioSpace, Fierce Biotech. Pitch angle: "small diagnostics team, real platform, here's the proof across 5 cancers."

During — Release week

PRESS RELEASE

Tue Aug 4 — OTraces Platform Capabilities PR goes live on GlobeNewswire (investor + tech distribution)

→📞 Day-of media pitch push (within 2 hours of wire): Sasha + Alan personally email every reporter on pre-built IVD/biotech list. Pitch the platform-not-test framing. (BioBuzz-proven tactic — typically 3–5× the pickup of wire-only.)

→Alan's pulse article goes live same day

→Pitch 360Dx, GenomeWeb, BioWorld MedTech, In Vivo

After — Convert attention

EVENT — CONVERT ATTENTION

Jul 26–30 — ADLM (formerly AACC) Clinical Lab Expo, Anaheim — Alan attends with Labcorp partnership as the conversation starter. PR drops 12 days before the show. Lab industry's biggest annual gathering.

Target audience here: Roche Dx, Abbott Dx, Siemens Healthineers, Sysmex, bioMérieux, BD.

→Mendelspod / Diagnostics World podcast pitches

→Use platform framing in all investor outreach going forward

Named IVD platform targets

Roche DxAbbott DxSiemens HealthineersSysmexbioMérieuxBD

Platform-pattern investors

ARCH VenturePolarisOrbiMedForesite Capital

Owner: Alan + Sasha

Tuesday September 15, 2026 (pre-CAP, 18 days before pathologist conference)

Prostate Cancer as Lead Product — Partnership Ask

The explicit "we're open for partnership" releaseHeadline: OTraces names lead product, opens licensing discussions

PartnersInvestors

Before — Build the runway

→Alan confirms positioning: license-only vs. open to co-development
→Decide which partners to name in outreach vs. pursue silently
→Draft full PR (does not exist yet)
→Coordinate with Johns Hopkins University (JHU) comms for parallel announcement
→Build day-of media pitch list: Endpoints News, STAT, Fierce Biotech, BioSpace, BioWorld MedTech, Diagnostics World, In Vivo. Pitch angle: "diagnostics company opens for partnership conversations with JHU-validated 98%/95% prostate test."

During — Release week

PRESS RELEASE

Tue Sep 15 — Partnership Ask PR goes live on GlobeNewswire + Business Wire

→📞 Day-of media pitch push (within 2 hours of wire): Sasha + Alan personally email every reporter on pre-built pharma/diagnostics partnership list. (BioBuzz-proven tactic — typically 3–5× the pickup of wire-only.)

→Direct partner outreach with personalized notes

→JHU / Brady Urology co-release if possible

→Pitch BioWorld MedTech, Diagnostics World, In Vivo

After — Convert attention

→Aggressive BD follow-up on every inbound

EVENT — CONVERT ATTENTION

Oct 3–6 — CAP Annual Meeting (Wynn Las Vegas) — Alan attends with the Partnership Ask as the opener. PR drops 18 days before.

Target audience here: Reference lab BD teams (Quest, Sonic, BioReference); pathology leaders.

→Spring 2027 events: AACR Apr 2–7 + AUA May 21–24 + ASCO Jun 4–8 — book pharma + urology meetings off this release

→Track conversions: meetings → term sheets → deals

Licensing/diagnostic targets

Exact Sciences/AbbottGuardant HealthNateraVeracyteRoche

Pharma needing patient ID

PfizerAstraZenecaJanssenBayer Oncology

Owner: Alan (positioning) + Sasha (draft)

Tuesday October 6, 2026 — PENDING (pre-AdvaMed MedTech, 12 days before)

Patents — IP Moat Story

Angle: cross-domain patents prove the math is general-purpose

Investors

Owner: Reference: patent list in white paper + tech presentation

Tuesday October 27, 2026 — PENDING (pre-HLTH, 19 days before Nov 15 payer conference)

FDOH + Labcorp Three-Way Partnership Angle

Angle: state agency + Tier-1 lab + innovator as a replicable template

PartnersGrants

Owner: May overlap with PR #5 — coordinate scope

Tuesday December 1, 2026 — PENDING (pre-JPM Healthcare 2027, 6 weeks lead for investor audience)

TrialNet T1D Collaboration

Angle: how OTraces+TrialNet is reshaping T1D progression predictionTargets: T1D pharma (Sanofi, Vertex, Provention/Sanofi, MacroGenics, Lilly, Novo) + foundations (JDRF, Helmsley Charitable Trust, Diabetes Research Connection) + investors at JPM

PartnersGrantsInvestors

Owner: Reference: TrialNet manuscripts + T1D study report